JPRN-jRCT2080223100已完成3 期
A Phase 3, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with histologically or cytologically documented, unresectable, Stage IV transitional cell carcinoma of the urothelium who have not been previously treated with first-line chemotherapy.
- •- Patients eligible or ineligible for cisplatin-based chemotherapy.
- •Cisplatin ineligibility is defined as meeting 1 of the following criteria:
- •Creatinine clearance (calculated or measured) <60 mL/min calculated by Cockcroft-Gault equation (using actual body weight) or by measured 24-hour urine collection for determination, Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or more audiometric hearing loss, CTCAE Grade 2 peripheral neuropathy, New York Heart Association Class III heart failure.
- •- Tumor PD-L1 status, with Immunohistochemical (IHC) assay confirmed by a reference laboratory, must be known prior to randomization.
排除标准
- •- Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.
- •- History of allogenic organ transplantation that requires use of immunosuppressive agents.
- •- Active or prior documented autoimmune or inflammatory disorders.
- •The following are exceptions to this criterion:
- •Patients with vitiligo or alopecia, Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement, Any chronic skin condition that does not require systemic therapy, Patients without active disease in the last 3 years may be included but only after consultation with AstraZeneca, Patients with celiac disease controlled by diet alone may be included but only after consultation with AstraZeneca.
- •- Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids for at least 14 days prior to the start of study treatment. Patients with suspected or known brain metastases at screening should have an MRI (preferred)/CT, preferably with IV contrast to access baseline disease status.
- •- Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- •- Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP).
- •The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection), Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent, Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
- •- Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational product (IP).
研究者
相似试验
进行中（未招募）
不适用
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refacroty amyloidosis.Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisMedDRA version: 15.0Level: PTClassification code 10024459Term: Light chain diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005468-10-ITMILLENNIUM PHARMACEUTICALS, INC.248
已完成
3 期
OlympiADBreast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene MutationJPRN-jRCT2080222477AstraZeneca
进行中（未招募）
1 期
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refractory amyloidosis.EUCTR2011-005468-10-ESMillennium Pharmaceuticals, Inc.177
进行中（未招募）
1 期
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refractory amyloidosis.Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisEUCTR2011-005468-10-DEMillennium Pharmaceuticals, Inc.248
进行中（未招募）
1 期
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refractory amyloidosis.Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisEUCTR2011-005468-10-DKMillennium Pharmaceuticals, Inc.248